Following clinical use of the ODxTT, the Amoy Dx® Pan Lung Cancer PCR panel (AmoyDx-multi) (Amoy Diagnostics Co., Ltd., Xiamen, China), a multi-PCR panel which can detect a total of 11 genes, including 4 genes using DNA and 7 genes using RNA, has been approved for use in Japan since June 2021 as a companion diagnostic for targeted therapies on four driver alterations: EGFR mutations, ALK fusions, ROS1 fusions, and BRAF V600E mutations. The gene discussed is ALK; the disease is lung cancer.